Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
127.5 USD | -0.58% | -2.80% | +16.97% |
May. 02 | Merck: encouraging results in gastric cancer | CF |
May. 01 | Merck Says Keytruda Meets Primary Endpoint in Late-Stage Gastric Cancer Trial | MT |
Chart calendar Merck & Co., Inc.
Upcoming events on Merck & Co., Inc.
Past events on Merck & Co., Inc.
2024-04-25 09:00 am | Q1 2024 Earnings Call |
2024-04-25 06:30 am | Q1 2024 Earnings Release |
2024-03-13 | Ex-dividend day |
2024-03-12 03:05 pm | Barclays Global Healthcare Conference |
2024-03-11 12:40 pm | Leerink Partners Global Biopharma Conference |
2024-03-05 01:30 pm | TD Cowen Health Care Conference |
2024-02-01 09:00 am | Q4 2023 Earnings Call |
2024-02-01 06:30 am | Q4 2023 Earnings Release |
2024-01-25 | American Society of Clinical Oncology Genitourinary Cancers Symposium - Abstract No : #LBA531 |
2024-01-08 07:30 pm | JPMorgan Healthcare Conference |
2024-01-04 12:45 pm | Goldman Sachs Healthcare C-Suite Unscripted Conference |
2023-12-13 | Ex-dividend day |
2023-12-06 | European Society for Medical Oncology Immuno Oncology Congress - Abstract No:121P |
2023-11-30 01:20 pm | Evercore ISI HealthCONx Conference |
2023-11-16 05:00 am | Jefferies London Healthcare Conference |
2023-11-08 12:00 pm | UBS BioPharma Conference |
2023-10-26 09:00 am | Q3 2023 Earnings Call |
2023-10-26 06:30 am | Q3 2023 Earnings Release |
2023-10-22 01:00 pm | European Society for Medical Oncology Congress |
2023-10-20 10:15 am | European Society for Medical Oncology Congress - Abstract No. - #LBA38 |
Past dividends on Merck & Co., Inc.
2024-03-13 | Quarterly 0.77 USD |
2023-12-13 | Quarterly 0.77 USD |
2023-09-13 | Quarterly 0.73 USD |
2023-06-13 | Quarterly 0.73 USD |
2023-03-13 | Quarterly 0.73 USD |
2022-12-13 | Quarterly 0.73 USD |
2022-09-13 | Quarterly 0.69 USD |
2022-06-13 | Quarterly 0.69 USD |
2022-03-13 | Quarterly 0.69 USD |
2021-12-13 | Quarterly 0.69 USD |
Annual results
Fiscal Period | December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|---|---|
Net sales Million USD | Released Forecast Spread | 46 840 46 818 0.05% | 47 994 48 177 -0.38% | 48 704 48 367 0.7% | 59 283 59 144 0.24% | 60 115 59 938 0.3% | 64 108 |
EBITDA Million USD | Released Forecast Spread | 19 572 18 761 4.32% | 20 570 19 815 3.81% | 20 910 19 760 5.82% | 26 431 24 588 7.5% | 10 083 9 362 7.71% | 29 296 |
EBIT Million USD | Released Forecast Spread | 15 920 16 276 -2.19% | 16 945 17 366 -2.43% | 17 696 17 554 0.81% | 22 522 22 363 0.71% | 6 211 6 066 2.4% | 26 199 |
Earnings before Tax (EBT) Million USD | Released Forecast Spread | 11 464 12 277 -6.62% | 8 791 14 906 -41.02% | 13 879 12 048 15.2% | 16 444 17 389 -5.44% | 1 889 2 857 -33.89% | 23 936 |
Net income Million USD | Released Forecast Spread | 9 843 9 957 -1.15% | 7 067 12 094 -41.57% | 13 049 11 797 10.61% | 14 519 14 827 -2.07% | 365 1 682 -78.3% | 19 510 |
EPS USD | Released Forecast Spread | 3,81 3,83 -0.52% | 2,78 4,71 -41% | 5,14 4,70 9.39% | 5,71 5,87 -2.73% | 0,14 0,56 -75.16% | 7,74 |
Announcement Date | 05/02/20 | 04/02/21 | 03/02/22 | 02/02/23 | 01/02/24 | - |
Quarterly results
Fiscal Period | December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales Million USD | Released Forecast Spread | 13 521 13 212 2.34% | 15 901 14 648 8.55% | 14 593 13 861 5.28% | 14 959 14 043 6.52% | 13 830 13 676 1.12% | 14 487 13 799 4.98% | 15 035 14 450 4.05% | 15 962 15 273 4.51% | 14 630 14 480 1.03% | 15 775 15 204 3.75% | 15 822 | 16 666 | 15 959 | 16 565 |
EBITDA Million USD | Released Forecast Spread | 5 670 4 892 15.91% | 7 568 5 918 27.88% | 6 649 6 064 9.65% | 6 516 6 275 3.85% | 5 698 5 183 9.94% | 5 402 5 058 6.8% | -3 485 -3 901 10.67% | 7 538 6 724 12.1% | 665 1 985 -66.49% | 6 562 | 7 353 | 8 225 | 7 640 | |
EBIT Million USD | Released Forecast Spread | 4 835 4 528 6.79% | 6 448 5 393 19.56% | 5 711 5 157 10.75% | 5 557 5 268 5.49% | 4 806 4 592 4.66% | 4 411 4 088 7.89% | -4 388 -4 683 6.29% | 6 524 5 967 9.33% | -299 -476 37.23% | 6 383 5 808 9.91% | 6 504 | 7 018 | 6 280 | |
Earnings before Tax (EBT) Million USD | Released Forecast Spread | 3 583 3 956 -9.43% | 3 513 3 391 3.6% | 3 650 4 190 -12.89% | -5 335 -4 682 -13.95% | 5 620 5 023 11.89% | -2 046 -1 249 -63.78% | 5 670 5 267 7.66% | 6 041 | 6 455 | 5 769 | ||||
Net income Million USD | Released Forecast Spread | 3 758 3 557 5.64% | 4 310 3 768 14.4% | 3 944 3 859 2.19% | 3 248 3 477 -6.6% | 3 017 3 016 0.02% | 2 821 3 133 -9.97% | -5 975 -6 154 2.9% | 4 745 4 224 12.34% | -1 226 -919 -33.43% | 4 762 4 414 7.88% | 4 953 | 5 440 | 4 822 | |
EPS USD | Released Forecast Spread | 1,48 1,35 9.77% | 1,70 1,48 14.96% | 1,55 1,48 4.46% | 1,28 1,42 -10.11% | 1,18 1,20 -1.99% | 1,11 1,21 -8.14% | -2,35 -2,44 3.61% | 1,86 1,65 12.59% | -0,48 -0,35 -37.91% | 1,87 1,79 4.45% | 1,94 | 2,12 | 1,95 | |
Announcement Date | 03/02/22 | 28/04/22 | 28/07/22 | 27/10/22 | 02/02/23 | 27/04/23 | 01/08/23 | 26/10/23 | 01/02/24 | 25/04/24 | - | - | - | - |
Past sector events for Merck & Co., Inc.
2024-05-03 06:00 am | AMNEAL PHARMACEUTICALS, INC.: Q1 2024 Earnings Release |
2024-05-02 | SCINOPHARM TAIWAN, LTD.: Q1 2024 Earnings Release (Projected) |
2024-05-02 | AARTI DRUGS LIMITED: Q4 2024 Earnings Release |
2024-05-02 | DEVA HOLDING: Q1 2024 Earnings Release (Projected) |
2024-05-02 04:01 pm | AMGEN INC.: Q1 2024 Earnings Release |
2024-05-02 01:43 pm | ALK-ABELLÓ A/S: Q1 2024 Earnings Release |
2024-05-02 07:30 am | ORGANON & CO.: Q1 2024 Earnings Release |
2024-05-02 07:00 am | BAUSCH HEALTH COMPANIES INC.: Q1 2024 Earnings Release |
2024-05-02 01:30 am | NOVO NORDISK A/S: Q1 2024 Earnings Release |
2024-05-01 | GC BIOPHARMA CORP.: Q1 2024 Earnings Release |
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- MRK Stock
- Calendar Merck & Co., Inc.